{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:35:10Z","timestamp":1784759710023,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ygyno.2024.01.048","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T13:58:59Z","timestamp":1708005539000},"page":"25-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions"],"prefix":"10.1016","volume":"185","author":[{"given":"Evi","family":"Abada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejeong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Kheil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaljeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeshna","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouba","family":"Ali-Fehmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ruhul","family":"Quddus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.01.048_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2024.01.048_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0015","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000002030","article-title":"HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy [published online ahead of print, 2023 Mar 20]","author":"Joehlin-Price","year":"2023","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.01.048_bb0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2015.01.533","article-title":"HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant","volume":"137","author":"Growdon","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"Suppl. 7","key":"10.1016\/j.ygyno.2024.01.048_bb0030","doi-asserted-by":"crossref","first-page":"vii36","DOI":"10.1093\/annonc\/mdq421","article-title":"Treatment of HER2-overexpressing breast cancer","volume":"21","author":"Baselga","year":"2010","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.01.048_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0040","article-title":"Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: report of scenarios of unusual overexpression","volume":"32","author":"Quddus","year":"2020","journal-title":"Gynecol Oncol. Rep."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0050","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0055","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41379-021-00746-5","article-title":"Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study","volume":"34","author":"Buza","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0060","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosom. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2024.01.048_bb0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ijgo.13866","article-title":"Cancer of the corpus uteri: 2021 update","volume":"155","author":"Koskas","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"7","key":"10.1016\/j.ygyno.2024.01.048_bb0070","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/PAS.0b013e31802ee494","article-title":"Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences","volume":"31","author":"Soslow","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"issue":"10","key":"10.1016\/j.ygyno.2024.01.048_bb0075","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.21873\/anticanres.11112","article-title":"Genomic characterisation and response to trastuzumab and paclitaxel in advanced or recurrent HER2-positive endometrial carcinoma","volume":"36","author":"Koskas","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0085","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13000-016-0553-8","article-title":"Systematic assessment of HER2\/neu\u00a0in gynecologic neoplasms, an institutional experience","volume":"11","author":"Woo","year":"2016","journal-title":"Diagn. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.01.048_bb0090","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/bjc.2017.422","article-title":"HER2 expression patterns in paired primary and metastatic endometrial cancer lesions","volume":"118","author":"Halle","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"15","key":"10.1016\/j.ygyno.2024.01.048_bb0095","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.01.048_bb0100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PGP.0000000000000674","article-title":"Equivalent survival of p53 mutated endometrial endometrioid Carcinoma grade 3 and endometrial serous carcinoma","volume":"40","author":"Brett","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2024.01.048_bb0110","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/PGP.0000000000000512","article-title":"Issues in the differential diagnosis of uterine low-grade endometrioid carcinoma, including mixed endometrial carcinomas: recommendations from the International Society of Gynecological Pathologists","volume":"38","author":"Rabban","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0115","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2024.01.048_bb0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early-stage uterine serous carcinoma: a multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.048_bb0125","article-title":"Low-level expression of human epidermal growth factor receptor-2 (HER2) in high-grade mullerian tumors: implications for therapy decision making","volume":"49","author":"Abada","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"issue":"15","key":"10.1016\/j.ygyno.2024.01.048_bb0130","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE Trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582400074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582400074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:35:15Z","timestamp":1732610115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582400074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":26,"alternative-id":["S009082582400074X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.048","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}